Rezolute's SWOT analysis: biotech stock advances on ersodetug trials
Rezolute , Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company, is making significant strides in the development ...
Rezolute: Late-Stage Study Targeting Hyperinsulinism
Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a ...
What is Wedbush’s Estimate for Rezolute FY2029 Earnings?
Wedbush boosted their FY2029 earnings estimates for shares of Rezolute in a report released on Thursday, February 13th.
Q1 Earnings Forecast for Rezolute Issued By HC Wainwright
Analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Rezolute in a research report issued on ...
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and ...
Rezolute to announce DMC conclusions in April, says H.C. Wainwright
Rezolute (RZLT) announced that the independent data monitoring committee reviewed safety and pharmacokinetics in eight infant patients in the ...
Yahoo Finance6d
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company ...
Morningstar6d
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation Open-label arm (infant ...
Hosted on MSN3d
Rezolute’s Strategic Advances in Rare Disease Therapies
Rezolute, Inc. ( ($RZLT) ) has released its Q2 earnings. Here is a breakdown of the information Rezolute, Inc. presented to its investors.